Julio C. Palmaz, M.D., FSIR, PhD
Ashbel Smith Professor, University of Texas Health Science Center at San Antonio
Dr. Palmaz received his MD in 1971 from the National University of La Plata, Argentina and completed his radiology specialty training at the University of California, Davis in 1980. Dr. Palmaz began his professional career in 1974 at San Martin University Hospital, Argentina, and was Chief of Special Procedures at Martinez Veterans Administration Hospital in 1981. In 1983, Dr. Palmaz joined the University of Texas Health Sciences Department of Radiology as Chief of Angiography and Special Procedures, and currently is Ashbel Smith Tenured Professor at the University of Texas Health Science Center, San Antonio.
Dr. Palmaz conceived and developed the first clinically successful balloon expandable vascular stent in the early 1980s. The Palmaz stent was the first intravascular stent approved by the FDA in 1991 and provided the generic basic design for all subsequent balloon expandable stents since. Dr. Palmaz’s initial device was used for the first successful abdominal aortic stent-grafts and transjugular intrahepatic portosystemic shunts, now also common procedures throughout the world. This device has found applications beyond the arterial system, including veins (peripheral, central, and pulmonary), the biliary ducts, and the tracheobronchial tree. As such, it has become part of the standard armamentarium of a broad spectrum of medial specialties.
Dr. Palmaz has remained very active in basic research, with specific interest and productivity in the area of cellular and molecular response to intravascular metallic stent placement. He was also instrumental in the design and execution of early clinical trials in the application of stents in coronary, and peripheral arteries. These trials became benchmarks for subsequent clinical investigations of metallic stents.
Dr. Palmaz has 50 issued patents (US, European, Canadian) and is the author of 30 books or book chapters and 106 peer-reviewed publications. He is a member of the editorial board for Circulation and is a reviewer for several other journals. For two years in a row, his patent on the balloon-expandable stent was recognized as one of the “Ten patents that changed the world,” published in Intellectual Property International magazine. His early stent research artifacts are now part of the medical collection of the Smithsonian Institutions. He continues to innovate on his initial designs, developing new endovascular devices.
Dr. Palmaz delivered the SIR Dotter Lecture in 2001 and was an SIR Gold Medalist in 2007. In January 2003 Dr. Palmaz received the Presidential Distinguished Scholar Award from the University of Texas San Antonio. He received the title of “Master of Interventional Cardiology” from the Argentina College of Cardiology and “Extraordinary Professor” from the National University of La Plata, Argentina. He also received honorary titles or awards from numerous societies around the world, including the International Society of Endovascular Surgery, the German Roentgen Society, The Rotterdam Thoraxcenter in Holland, the Society of Cardiac Angiography and the Cardiovascular Institute of the South. In 2006 he was inducted into the US National Inventors Hall of Fame, became a Fellow of the American Institute for Medical and Biological Engineering, and honored with a Medical Innovation Stent Exhibit at the Bob Bullock Texas State History Museum. In 2007 he received the Chancellor's Entrepreneurship and Innovation Award from the University of Texas System, and received the Society of Interventional Radiology (SIR) Gold Medal. In 2010 he was honored as a landmark medical innovator at the Cardiovascular Research Foundation's annual Pulse of the City Gala in New York."
Gregg W. Stone, M.D., FACC, FSCAI
Professor of Medicine, Columbia University
Director of Cardiovascular Research and Education Center for Interventional Vascular Therapy
New York Presbyterian Hospital/Columbia University Medical Center
Co-Director of Medical Research and Education
The Cardiovascular Research Foundation, New York, NY
Dr. Stone is Professor of Medicine at the Columbia University, Director of Cardiovascular Research and Education of the Center for Interventional Vascular Therapies at Columbia University Medical Center, and the Cardiovascular Research Foundation in New York, NY. Dr. Stone has served as the national or international principal investigator for more than 50 national and international multicenter randomized trials, has authored more than 1000 book chapters, manuscripts and abstracts published in the peer-reviewed literature, and has delivered thousands of invited lectures around the world. Dr. Stone's areas of expertise include interventional therapies of acute coronary syndromes and myocardial infarction; drug eluting stents; adjunct pharmacology; percutaneous heart valves, new device angioplasty including distal embolic protection, thrombectomy, vascular brachytherapy and stent grafts; intravascular ultrasound imaging; saphenous vein graft therapies; chronic total occlusions; vulnerable plaque; contrast nephropathy; clinical trial design; and regulatory issues. Along with Dr. Martin B. Leon, Dr. Stone is the director of Transcatheter Cardiovascular Therapeutics (TCT), the world's largest symposium devoted to interventional cardiology and vascular medicine, directs the annual National Interventional Cardiology Fellows’ Course, and co-directs several other annual courses, including The Drug-Eluting Stent Revolution: A Critical Appraisal, The Chronic Total Occlusion Summit, and Transcatheter Valve Therapies. Dr. Stone's medical practice is devoted to interventional cardiology at New York-Presbyterian Hospital/Columbia University Medical Center.
Dr. Stone previously held similar positions at Lenox Hill Hospital in New York and the Washington Hospital Center in Washington, DC. Previously he was the Director of Interventional Cardiology at the Cardiovascular Institute at El Camino Hospital and Stanford University Medical Center in California.
Dr. Stone completed medical school at Johns Hopkins University Medical Center, in Baltimore, MD, and his internship and residency at the New York Hospital-Cornell Medical Center in New York City. He completed his general cardiology fellowship at Cedars-Sinai Medical Center in Los Angeles, CA, under Dr. Jeremy Swan, and subsequently a dedicated fellowship in advanced coronary angioplasty with Dr. Geoffrey Hartzler in Kansas City, MO. Dr. Stone is board certified in Interventional Cardiology, Cardiovascular Diseases, and Internal Medicine.
Raoul Bonan, M.D., FACC, FESC, FSCAI
Associate Professor of Medicine, University of Montreal
Doctor Raoul Bonan has been working as an interventional cardiologist at the Montreal Heart Institute since 1978. He graduated from the Université de Paris (1974), and came to the Institute to complete his training in invasive cardiology (1972-1973). He then continued training in Montreal until 1978. Dr. Bonan is a Fellow of the American College of Cardiology, the European Society of Cardiology, the American Heart Association and the Society for Cardiac Angiography and Interventions.
In addition, beside his high involvement in the Medical Device Industry, Doctor Bonan is primary or co-author of over 190 scientific articles and 20 book chapters, particularly related to research on cardiovascular percutaneous interventions. He has now delivered more than 300 scientific presentations and has participated in numerous interventional cardiology live cases and demonstrations around the world. He continues to be a key player in the planning and organization of multiple scientific meetings.
Sarah Rinehart, M.D., FACC
Cardiovascular Imaging, Medical Director, Department of Cardiovascular CT and MRI,
Piedmont Heart Institute
Clinical Assistant Professor, Department of Medicine, Georgia Health Sciences University
Dr. Rinehart earned her bachelor’s degree from West Virginia Wesleyan College in Buckhannon, West Virginia and earned her medical degree from Marshall University School of Medicine in Huntington, West Virginia. She completed her internal medicine residency and cardiology fellowship at the Joan C. Edward School of Medicine, Marshall University. Sarah fulfilled her cardiac imaging fellowship in cardiovascular MRI and CT at Piedmont Hospital. Dr. Rinehart joins Szliard Voros, M.D. in the Fuqua Cardiovascular Imaging Center.
She is a member of the American College of Cardiology, American Medical Association, the American College of Physicians, the Society of Cardiovascular Computed Tomography and the Society of Cardiovascular Magnetic Resonance. Dr. Rinehart is board-certified in internal medicine and holds a level three cardiac CT/MR certification. She is heavily involved in cardiac research in areas such as atherosclerosis of the carotid and coronary arteries and prevention, specifically using cardiac CT/MR modalities.
Robert S. Schwartz, M.D., FACC, FAHA
Medical Director, Education, Minneapolis Heart Institute and Foundation
Dr. Schwartz grew up in Boulder, Colorado, enjoying and thriving in the academic community surrounding the University of Colorado. He is driven by a lifelong passion of understanding how things work and developing new technologies for medical application. He holds undergraduate and graduate degrees in Physics, Electrical Engineering, and Biomedical Engineering
He entered medical school with the goal to combine basic science, medical device technology, and clinical Cardiovascular practice. He completed postgraduate medical residencies and Fellowships in Internal Medicine and Cardiology at Mayo Clinic in Rochester, MN. After serving 4 years as a US Air Force Flight Surgeon, he accepted a Staff position in Cardiovascular Diseases at the Mayo Clinic, and established the Mayo Center for Applied Vascular Biology and Coronary Interventions. While in this role he was honored with the the prestigious Andreas Gruentzig Basic Research Award, given by the European Society of Cardiology.
To expand his involvement with the medtech/biotech community, he joined the Minneapolis Heart Institute in 2002 as a Clinician and Researcher, and founded the Minnesota Cardiovascular Research Institute. This institute is dedicated to novel technology and its medical applications. He currently practices Clinical Cardiology and is passionate about its interface with technology.
Dr. Schwartz has authored or co-authored more than 500 scientific publications and abstracts. He lectures extensively (nationally and internationally), and is a named inventor on 46 patents in medical devices and technology. He has co-founded several medical device companies, and enjoys consulting roles in the Medical Device Industry, Venture Capital, and the FDA.
Nicholas Lembo, M.D., FACC, FSCAI
Piedmont Heart Institute
Dr. Nicholas J. Lembo received his medical degree from Howard University College of Medicine in Washington, D.C. and was inducted into Alpha Omega Alpha, a medical honors society. He completed his internship and residency at Georgetown University Hospital and completed a fellowship in cardiology at the University of Texas Health Science Center in San Antonio, Texas with an additional year of fellowship in interventional cardiology at Emory University.
Dr. Lembo then joined the faculty at Emory University and was co-principal investigator of the NHLBI funded Emory Angioplasty vs. Surgery Trial (E.A.S.T.) and received the prestigious J. Willis Hurst Award for Excellence in Teaching for three consecutive years. Dr. Lembo has authored over 50 papers and abstracts including lead authorship in the New England Journal of Medicine, Circulation, American Journal of Cardiology and Annals of Internal Medicine.
He is board certified in internal medicine, cardiovascular diseases and interventional cardiology and is a fellow of the American College of Cardiology. He specializes in invasive and interventional cardiology and is the medical director of the Interventional Cardiology Center of Excellence at Piedmont Heart Institute.
Charles L. Brown, III, M.D., FACC, FSCAI
Chief Medical Officer, Piedmont Heart Institute
Dr. Charles L. Brown earned his undergraduate degree from the University of New Orleans in New Orleans, Louisiana. He earned his medical degree from Louisiana State University School of Medicine in New Orleans and completed his internship, residency and fellowships in cardiovascular disease and interventional cardiology with Emory University Affiliated Hospitals. During his cardiovascular disease fellowship, he served as chief resident of medicine and he fulfilled an additional fellowship in peripheral angioplasty at the Red Cross Hospital in Frankfurt, Germany.
Dr. Brown is board-certified in cardiovascular diseases, internal medicine, and interventional cardiology. He is also a member of numerous professional societies, including Alpha Omega Alpha, the American College of Cardiology, the American College of Physicians, the American Medical Association, the American Heart Association, the Medical Association of Atlanta and the Medical Association of Georgia.
Howard T. Walpole, Jr., MD, MBA, FACC, FSCAI
Chief Medical Officer, Okyanos Heart Institute
Howard Walpole is the Chief Medical Officer of Okyanos Heart Institute and former Chief of Cardiac Sciences at Saint Thomas Hospital in Nashville, Tennessee. Dr Walpole attended medical school at the Medical College of Georgia and completed internal medicine residency at Vanderbilt University. He completed general cardiology and interventional cardiology fellowships at Emory University. He also obtained an MBA from the Goizueta Business School at Emory. Dr. Walpole served as managing partner of Saint Thomas Heart for 10 years and was instrumental in completing its integration with Saint Thomas Health Services. He is board certified in internal medicine, cardiovascular diseases and interventional cardiology. Dr. Walpole is active in the American College of Cardiology where he served as governor of the Tennessee Chapter and is currently a member of the ACC Board of Trustees. He is the program director of the ACC’s Cardiovascular Summit and serves on the Cardiovascular Leadership Institute Work Group and the executive board of the ACC Political Action Committee.
President & CEO, MedAxiom Consulting
Suzette Jaskie, President and CEO of MedAxiom Consulting, is a health care industry thought leader with over 20 years of executive healthcare management experience in both physician practice and hospital environments. Ms. Jaskie has extensive experience in healthcare organizational development, strategic planning, hospital/physician alignment, improving financial, operations and market organization performance, market and program development, financial management and physician compensation. Suzette is a coach and a performance improver who relishes in motivating change and assisting organizations to achieve their optimal performance.
Previously, Suzette served as the CEO of West Michigan Heart, a 33-cardiologist practice, and Executive Director of Spectrum Health’s Frederik Meijer Heart & Vascular Institute, both in Grand Rapids. In that role, Ms. Jaskie provided executive management to both organizations, coordinating 98-physicians in several cardiovascular specialties across a 7 hospital, 14 county system. Ms. Jaskie is a frequent speaker at national meetings and a contributor to several journals and articles. She is a faculty member of American College of Cardiology’s Advanced Leadership Institute. Suzette has a Master’s Degree in Business Administration from the University Of Hartford, CT and a Bachelor of Science from the University of Wisconsin.
Sunil V. Rao, M.D.
Associate Professor of Medicine, Duke University Medical Center
Director, Cardiac Catheterization Laboratories, Durham VA Medical Center
Dr. Rao is an Associate Professor of Medicine at Duke University Medical Center, the Director of the Cardiac Catheterization Laboratories at the Durham VA Medical Center, and an Associate Editor of The American Heart Journal. Dr. Rao serves as a voting member of the Society for Cardiovascular Angiography and Interventions (SCAI) Transradial Committee, Quality Committee, and Simulation Committee. He is also a member of the American College of Cardiology’s Interventional Scientific Council, and serves on the program committees of the ACC-i2 Summit, the Transcatheter Cardiovascular Therapeutics conference, and the SCAI Scientific Sessions.
His main research interests deal with phase 2 clinical trials exploring the pharmacological and interventional therapies for acute coronary syndromes, as well as bleeding and blood transfusion complications among patients with ischemic heart disease. Dr. Rao was the national principal investigator (PI) the phase 2 EMINENCE trial of the novel heparin M118 in PCI, the national PI of the phase 2 INNOVATE-PCI trial of the novel antiplatelet agent PRT128 in PCI, and the co-PI for the NIH-funded REVEAL trial, which was a phase 2 randomized trial of intravenous erythropoietin in patients with acute ST-segment elevation MI. In addition, he is the national PI of the ACROSS-Cypher trial of the Cypher drug-eluting stent in patients with chronic total coronary occlusions, and the national PI for the SAFE-PCI for Women trial comparing the radial and femoral approaches to PCI in women. He also is a coinvestigator on the ACC-funded National Cardiovascular Data Regisry (ACC-NCDR). He serves as the US National Coordinator for the TAO study of the novel anticoagulant otamixaban and has served on the steering committees of the RIVAL and FUTURA clinical trials. His research has been published in leading medical journals including the American Heart Journal, the Journal of the American College of Cardiology, and JAMA. His wife Caroline is a Duke-trained internist and dermatologist who practices Duke and the Durham VA Medical Center. They have four daughters – Maya, age 12, Lily, age 10, Ava, age 7, and Grace, age 5.
David E. Kandzari, M.D., FACC, FSCAI
Director, Interventional Cardiology and Chief Scientific Officer
Piedmont Heart Institute
Dr. David E. Kandzari earned his undergraduate degree from Duke University School of Medicine then completed his internship and residency at The John Hopkins University School of Medicine in Baltimore, Maryland. Following his residency, he completed his general and interventional cardiology fellowship at Duke University where he joined the faculty as the John B. Simpson Assistant Professor of Interventional Cardiology and Genomic Sciences.
Dr. Kandzari is the former director of Interventional Cardiology Research at the Scripps Clinic in La Jolla, California. Before joining the Scripps faculty, he also served as chief medical officer for the Cordis Corporation, a Johnson & Johnson Company. He has also served as a medical officer for the Center for
Devices and Radiological Health for the United States Food and Drug Administration and is currently an ad hoc member of the FDA's Circulatory Devices Panel.
Dr. Kandzari has held national and international leadership roles in clinical trials in cardiovascular disease and has participated in national and international program committees in cardiology. He has authored and coauthored more than 150 studies, book chapters and scientific reviews and has delivered more than 300 lectures, both nationally and internationally, on a variety of issues related to both interventional and general cardiology.
Dr. Kandzari is board certified in internal medicine and cardiovascular diseases and is certified by the Board of Interventional Cardiology. He specializes in interventional cardiology, peripheral arterial disease and cardiovascular medicine. His clinical focus includes catheter-based revascularization of complex coronary and peripheral disease.
Mark Reisman, M.D., FACC, FSCAI
University of Washington Medical Center
Christopher J. White, M.D., FSCAI, FACC, FAHA, FESC
Ochsner Clinical School, University of Queensland
AMD for Medical Specialties and System Chair for Cardiovascular Diseases
Medical Director of the John Ochsner Heart & Vascular Institute
Dr. White graduated AOA from Case Western Reserve Medical School in Cleveland, Ohio in 1978 and completed his residency in Internal Medicine and fellowship training in Cardiovascular Diseases at Letterman Army Medical Center from 1978 thru 1983. He then joined the Staff of Letterman Army Medical Center as the Director of the Cardiac Catheterization Laboratory and Director of Cardiovascular Research in 1983. In 1985 he became the Director of the Catheterization Laboratory at Walter Reed Army Medical Center and Director of Cardiovascular Research until leaving active duty to become the Director of the Catheterization Laboratory at the Ochsner Clinic in 1988. In 1994, he moved to Scotland, to become the Director of Invasive Cardiology for HCI Medical Center in Glasgow until returning to Ochsner in 1997 as Chairman of the Department of Cardiology and Medical Director of the John Ochsner Heart & Vascular Institute. In 2013 he was named Chairman of the Department of Medicine at Ochsner. He has received Teacher of the Year awards at both Letterman and at Ochsner. He was recently honored as the Physician Leader of the Year at Ochsner and Mentor of the Year in the Department of Cardiology.
Dr. White recently completed two-terms as the Editor-in-Chief of Catheterization and Cardiovascular Interventions and currently serves as Associate Editor for Journal of the American College of Cardiology: Interventions. He is a Board Member for Accreditation for Cardiovascular Excellence (ACE) and the National Steering Committee Chairman for the NCDR-CARE registry. He has published more than 200 peer-reviewed manuscripts related to interventional cardiology and peripheral vascular diseases, including carotid stenting and acute stroke intervention. His major interests have centered on “device” development including developing an angioscope, a laser angioplasty catheter, and the Wiktor™ coronary stent. His current research interests involve systemic hypothermia for acute heart attacks, the development of appropriateness criteria for peripheral vascular interventions and stroke prevention with both intra-cranial and extra-cranial stent placement.
Arthur Reitman, M.D.
Timothy Henry, M.D., FACC
Director of Research at the Minneapolis Heart Institute Foundation
Dr. Henry is an interventional cardiologist at the Minneapolis Heart Institute/Abbott Northwestern Hospital and Professor of Medicine at University of Minnesota School of Medicine. Dr. Henry graduated from medical school at University of California, San Francisco, in 1982 and was chief medicine resident from 1982–1986 at University of Colorado Health Sciences Center. He completed his training as a cardiology fellow, chief cardiology fellow, and interventional cardiology fellow at University of Minnesota in 1991. His research interests include interventional cardiology, acute myocardial infarction, and novel therapies, including stem cell and gene therapy, for patients who are not candidates for standard revascularization techniques. Dr. Henry has published over 300 manuscripts and book chapters and has served on the Research Committee for the Minnesota Affiliate of the AHA and the Emergency Care Committee for the ACC; he currently serves on the Advisory Committee for the AHA Mission: Lifeline Program, the AHA Acute Cardiac Care Committee of the Council on Clinical Cardiology and on the ACC Interventional Subcommittee. He has served as national principal investigator of multiple large, multicenter trials in acute coronary syndromes, myocardial infarction and angiogenesis including several ongoing cardiovascular stem cell trials including RENEW, ALLSTAR and ATHENA. He is also principal investigator for 1 of 7 NIH Clinical Cardiovascular Stem Cell Centers. He is a fellow at ACC and SCAI and a member of Alpha Omega Alpha and the AHA Council on Clinical Cardiology.
David Feldman, M.D., PhD, FACC, FAHA
Medical Director of Heart Failure, VAD and Cardiac Transplant
Minneapolis Heart Institute/Abbott Northwestern Hospital
Adjunct Associate Professor, Georgia Institute of Technology and Morehouse Medical School
Dr. Feldman completed his training at Washington University-Barnes Hospital and Duke University Medical Center. Prior to his move to Minnesota, he was previously the Director of Heart Failure and Cardiac Transplant at The Ohio State University (OSU), USA, as well as one of the Associate-directors of the fellowship program at OSU. He had appointments in the Departments of Cardiovascular Medicine, Physiology, Cell Biology and the school of Pharmacy.
Dr. Feldman’s research interests include the study of G-protein coupled receptors, mechanisms of heart failure, genomic-mediated developmental changes, shock and cardiac transplantation. He is currently funded by multiple National Institute of Health grants and the Swiss Transplant Funding Grant. His research endeavors have included both basic and clinical research as he has extensive publications in both clinical and basic science. Despite his research, Dr. Feldman continues to have a busy clinical practice. His clinical focus is cardiac transplant, end-stage disease management, and critical care.
He is also the Editor for the International Society of Heart and Lung Transplant (ISHLT) newspaper and is on the Editorial Boards for the Journal of Cardiac Failure and Journal of Cardiovascular Translational Science. He reviews for more than a dozen peer reviewed journals including Nature, Circulation, Circulation Research, JACC, Journal of Heart and Lung Transplant, American Journal of Cardiology, and PACE among others. He’s an active member of several study sections and has been elected to America’s Top Doctors for the last 5 years in a row.
Chuck Ballard, M.D., FACC, FSCAI
Medical Director, Cardiac Network
Piedmont Heart Institute
Dr. William Ballard received his undergraduate degree from the University of Virginia in Charlottesville, Virginia. He received his medical degree from the Eastern Virginia Medical School in Norfolk, Virginia in three years where he was president of his class and was honored with the Franklin Award for most outstanding student in the Department of Medicine. He completed his internship and residency in medicine as well as his cardiology fellowship at the Medical University of South Carolina in Charleston, South Carolina where he was also bestowed with the Rosemond Award for Most Outstanding Cardiology Fellow. He then moved to Atlanta and began working for Piedmont Hospital in 1992.
Dr. Ballard has authored and edited several scientific papers, participated in more than 100 multi-center research trials as an investigator and was one of the authors of national certification guidelines for interventional cardiac procedures for the ACC/AHA. He has been director of the Cardiac Cath Lab and Coronary Intervention at Piedmont for over a decade. He is also a member of the Institutional Review Board and is currently director of Inpatient Quality and Safety for the Piedmont Heart Institute, physician director of the STEMI program and is cardiology director of the Chest Pain Center and Network and Mission Lifeline for PHI.
Dr. Ballard is board certified in internal medicine and cardiovascular disease. He is a fellow of the American College of Cardiology, Fellow of the Society for Cardiovascular Angiography and Interventions and is a member of the American Heart Association and the American Society of Nuclear Cardiology. He is also a clinical assistant professor of medicine at Georgia Health Sciences University.
Michael R. Mooney, M.D., FACC
Dr. Mooney is a researcher and interventional cardiologist. Dr. Mooney's research interests include therapeutic hypothermia, new devices, left atrial appendage occlusion, PFO closure and stroke prevention, and percutaneous aortic valve replacement.
Dr. Mooney is also Co-director of cardiovascular labs and Director, Interventional Cardiology, at the Minneapolis Heart Institute® at Abbott Northwestern Hospital.
Dr. Mooney has published more than 100 manuscripts and abstracts. He is a member of Alpha Omega Alpha and Hennepin County Medical Society. He is a Fellow of the American College of Physicians, American Heart Association and the Society for Cardiovascular Angiography and Interventions. He is an Associate Professor of Medicine at the University of Minnesota. He trains Fellows in Interventional Cardiology. Dr. Mooney speaks all over the world to help physicians initiate therapeutic hypothermia programs.